Douglas Evan Godshall - 15 Nov 2023 Form 4 Insider Report for Shockwave Medical, Inc.

Signature
s/ Wade Estey, as attorney-in-fact for Douglas Godshall
Issuer symbol
N/A
Transactions as of
15 Nov 2023
Net transactions value
-$853,327
Form type
4
Filing time
17 Nov 2023, 20:00:52 UTC
Previous filing
15 Nov 2023
Next filing
18 Dec 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWAV Common Stock Sale $188,716 -1,100 -0.78% $171.56 139,957 15 Nov 2023 Direct F1, F2
transaction SWAV Common Stock Sale $155,538 -900 -0.64% $172.82 139,057 15 Nov 2023 Direct F1, F3
transaction SWAV Common Stock Sale $86,965 -500 -0.36% $173.93 138,557 15 Nov 2023 Direct F1, F4
transaction SWAV Common Stock Sale $207,680 -1,186 -0.86% $175.11 137,371 15 Nov 2023 Direct F1, F5
transaction SWAV Common Stock Sale $160,699 -914 -0.67% $175.82 136,457 15 Nov 2023 Direct F1, F6
transaction SWAV Common Stock Sale $70,808 -400 -0.29% $177.02 136,057 15 Nov 2023 Direct F1, F7
transaction SWAV Common Stock Options Exercise $17,080 +5,000 +3.7% $3.42 141,057 15 Nov 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWAV Stock Option Options Exercise $0 -5,000 -1.5% $0.000000 329,799 15 Nov 2023 Common Stock 5,000 $3.42 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023.
F2 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $171.16 to $172.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F3 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $172.30 to $173.09. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $173.44 to $174.38. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F5 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $174.48 to $175.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F6 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $175.48 to $176.31. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F7 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $176.65 to $177.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F8 Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares vested in equal monthly installments.